I think it's plausible that PCYC could see single digit royalties net of the royalties due CRA. That obviously will depend on the specific deal terms they can strike with a big pharma partner (I know they already have one partner in Servier and not sure of the specifics of those deal terms). But if we assume a 15% royalty due PCYC on a given drug candidate, then obviously just a 6% royalty due CRA brings the net royalties due PCYC down to single digits.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.